Active, not recruitingPhase 3NCT04487080
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Amivantamab(drug)
- Enrollment
- 1074 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Arizona Oncology Associates, PC - HAL, Goodyear, Arizona, United States
- Yuma Regional Medical Center, Yuma, Arizona, United States
- City of Hope Long Beach Elm, Long Beach, California, United States
- University of California Irvine, Orange, California, United States
- Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
- Cancer Specialists of North Florida, Jacksonville, Florida, United States
- University Cancer And Blood Center LLC, Athens, Georgia, United States
- East Jefferson General Hospital, Metairie, Louisiana, United States
- Maryland Oncology Hematology, PA, Columbia, Maryland, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Minnesota Oncology Hematology P A, Edina, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School Of Medicine, St Louis, Missouri, United States
- Astera Cancer Care, East Brunswick, New Jersey, United States
- Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04487080 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →